ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2168-2174

  Tang, Ying ^a   Hou, Jingming ^b   Li, Guanghui ^a   Song, Zongchang ^a   Li, Xiaojing ^a   Yang, Cui ^a   Liu, Wenying ^a   Hu, Yide ^a   Xu, Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ABCG2; Asymmetric division; Drug resistance; NSCLC; Symmetric division

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; SHORT HAIRPIN RNA; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ABCG2 GENE; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL RENEWAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; GENE CONTROL; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; NON SMALL CELL LUNG CANCER; ONCOGENE; PHENOTYPE; STAINING; CELL DIVISION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS;

EID: 84907281082     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3470     Document Type: Article

References (28)

1. Bunn PA Jr and Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100, 1998.
2. Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141, 1998.
3. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
4. Robey RW, To KK, Polgar O, et al: ABCG2: a perspective. Adv Drug Deliv Rev 61: 3-13, 2009.
5. Nakamura Y, Oka M, Soda H, et al: Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546, 2005.
6. Yoh K, Ishii G, Yokose T, et al: Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10: 1691-1697, 2004.
7. Sereti KI, Oikonomopoulos A, Unno K, Cao X, Qiu Y and Liao R: ATP-binding cassette G-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells. Circ Res 112: 27-34, 2013.
8. Lathia JD, Hitomi M, Gallagher J, et al: Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2: e200, 2011.
9. Gonzalez C: Spindle orientation, asymmetric division and tumour suppression in Drosophila stem cells. Nat Rev Genet 8: 462-472, 2007.
10. Chen Z, Liu F, Ren Q, et al: Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 126: 841-851, 2010.
11. To KK, Robey RW, Knutsen T, Zhan Z, Ried T and Bates SE: Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther 8: 2959-2968, 2009.
12. Litman T, Brangi M, Hudson E, et al: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000.
13. Lanzkron SM, Collector MI and Sharkis SJ: Hematopoietic stem cell tracking in vivo: a comparison of short-term and long-term repopulating cells. Blood 93: 1916-1921, 1999.
14. Doyle L and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
15. Ueda T, Brenner S, Malech HL, et al: Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo. J Biol Chem 280: 991-998, 2005.
16. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
17. Ikuta K, Takemura K, Sasaki K, et al: Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28: 707-712, 2005.
18. Xu J, Peng H and Zhang JT: Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem 14: 689-701, 2007.
19. Doyle LA, Yang W, Abruzzo LV, et al: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
20. Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64: 98-104, 2009.
21. Morrison SJ and Kimble J: Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441: 1068-1074, 2006.
22. Knoblich JA: Mechanisms of asymmetric stem cell division. Cell 132: 583-597, 2008.
23. Shahriyari L and Komarova NL: Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? PLoS One 8: e76195, 2013.
24. Zhang R, Zhang Z, Zhang C, et al: Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat. J Neurosci 24: 5810-5815, 2004.
25. Barr MP, Gray SG, Hoffmann AC, et al: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193, 2013.
26. Susanto J, Lin YH, Chen YN, et al: Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS One 3: e4023, 2008.
27. Cicalese A, Bonizzi G, Pasi CE, et al: The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138: 1083-1095, 2009.
28. Kim JJ and Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Rev Cancer 5: 516-525, 2005.